Skip to main content

Artiva Biotherapeutics, Inc.

corporate_fare Company Profile

Artiva Biotherapeutics, Inc.

ARTV·NASDAQ·Life Sciences·CIK 0001817241

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company developing natural killer (NK) cell-based therapies for autoimmune diseases and cancers. The company's product candidates are derived from donor cells (allogeneic), pre-manufactured, and stored frozen for immediate shipment, making them "off-the-shelf." Artiva's lead product candidate is AlloNK (also known as AB-101), an allogeneic, non-genetically modified, cryopreserved NK cell therapy. AlloNK is designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of monoclonal antibodies (mAbs) to drive B-cell depletion. The company is evaluating AlloNK in three ongoing clinical trials for B-cell driven autoimmune diseases, including a company-sponsored basket trial that includes rheumatoid arthritis (RA) and Sjögren's disease (SjD). Refractory RA is the lead indication for AlloNK development. In November 2025, Artiva reported data from 32 patients with autoimmune disease treated with AlloNK plus anti-CD20 monoclonal antibody (mAb) as of October 1, 2025. This data showed consistent and complete B-cell depletion by Day 13 of treatment in all patients treated with AlloNK + mAb with samples analyzed.

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 28 items for ARTV at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Artiva Biotherapeutics Announces Public Offering of Common Stock and Pre-Funded Warrants
  • Artiva Biotherapeutics Details Positive AlloNK Clinical Data and FDA Alignment for Phase 3 RA Trial in Q1 Report
  • Artiva Biotherapeutics Announces Positive AlloNK Clinical Data and FDA Alignment for Phase 3 RA Trial
  • Artiva Biotherapeutics Amends 10-K to Complete Executive, Governance, and Ownership Disclosures
  • Artiva Biotherapeutics Reports Increased 2025 Net Loss, Extends Cash Runway to Q2 2027, and Advances AlloNK Autoimmune Program

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$0
Net Income
-$83.86M
Diluted EPS
-$3.43
Op. Cash Flow
-$76.75M
Free Cash Flow
-$79.34M
Operating Income
-$89.81M
Cash & Equivalents
$26.7M
Debt / Equity
0.00×
Shares Outstanding
24.44M sh
Source: 10-K · filed 2026-04-30 · accession 0001193125-26-197115
$3.82 +1.06% today
52-week range · as of 2026-11-09 $2.96 – $14.53
Market cap
$186.85M
Volume
1.8M (1.5× avg)
3-mo avg 1.2M
Live data · 2026-11-22 12:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ARTV - Filings & News (Page 2)

ARTV
May 08, 2026, 6:46 AM EDT
Filing Type: FWP
Importance Score:
8
Price at Filing: $13.83
Real-time Price: $3.82 info
Change: -$10.01 (-72%) info
Market Cap: $186.854M info
ARTV
May 08, 2026, 6:40 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $15.05
Real-time Price: $3.82 info
Change: -$11.23 (-75%) info
Market Cap: $186.854M info
ARTV
May 08, 2026, 6:37 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $15.15
Real-time Price: $3.82 info
Change: -$11.33 (-75%) info
Market Cap: $186.854M info
ARTV
Apr 30, 2026, 4:01 PM EDT
Filing Type: 10-K/A
Importance Score:
7
Price at Filing: $9.66
Real-time Price: $3.82 info
Change: -$5.84 (-60%) info
Market Cap: $186.854M info
ARTV
Mar 10, 2026, 4:09 PM EDT
Filing Type: 10-K
Importance Score:
7
Price at Filing: $6.08
Real-time Price: $3.82 info
Change: -$2.26 (-37%) info
Market Cap: $186.854M info
ARTV
Mar 10, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.08
Real-time Price: $3.82 info
Change: -$2.26 (-37%) info
Market Cap: $186.854M info
ARTV
Feb 24, 2026, 5:14 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.99
Real-time Price: $3.82 info
Change: -$1.17 (-23%) info
Market Cap: $186.854M info
ARTV
Feb 19, 2026, 5:20 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.53
Real-time Price: $3.82 info
Change: -$0.710 (-16%) info
Market Cap: $186.854M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets